Please use this identifier to cite or link to this item: http://hdl.handle.net/10603/338946
Full metadata record
DC FieldValueLanguage
dc.coverage.spatial
dc.date.accessioned2021-09-03T05:12:37Z-
dc.date.available2021-09-03T05:12:37Z-
dc.identifier.urihttp://hdl.handle.net/10603/338946-
dc.description.abstractThe present study was carried to evaluate the safety and efficacy of the siddha herbo mineral drug, Kara sooda sathu parpam in the management of Kalladaippu noi (Urolithiasis) with animal experimentations and in vitro methods. The drug analysis was also carried out to explore the chemical nature of the drug. The drug analysis revealed the presence of elements like calcium, sodium, boron, potassium, magnesium, zinc and iron. The groups present were carbonate, sulphate, chloride and nitrate. The XRD revealed the presence of calcium in oxide and carbonate form. The particle size ranged from nano to micro size which enhances the bioavailability of the drug. In vitro anti-oxidant studies revealed that the drug is a good antioxidant and is efficacious as that of ascorbic acid both in DPPH and Nitric oxide scavenging assays. The drug inhibited the growth of calcium oxalate crystals in vitro by single diffusion gel growth technique and the inhibition was dose dependent manner. The drug exhibited a moderate anti-microbial activity against E.coli and Proteus mirabilis, which are the most common pathogens causing UTI on patients suffering from urolithiasis. The acute and long term toxicity study revealed that the drug KSSP was safe up to 10 times the therapeutic dose as mentioned in the literature. The histopathological studies supported the same. The diuretic study revealed that the drug KSSP increased the urine output and also the excretion of electrolytes. The activity was in par with the standard drug. The drug also showed potent anti-inflammatory activity. To conclude the drug KSSP exerts its beneficial effect in Kalladaippu noi (Urolithiasis) by being a good anti urolithiatic, diuretic, antioxidant, anti-inflammatory and a moderate anti-microbial. The drug Kara sooda sathu parpam (KSSP) should be subjected to clinical trial to validate the efficacy of the drug for human use. The drug is also recommended to be validated for its preventive effects and also as a supportive therapy to other conventional medical expulsive therapies.
dc.format.extent320
dc.languageEnglish
dc.relation
dc.rightsuniversity
dc.titlePreclinical evaluation of safety and therapeutic efficacy of siddha herbo mineral compound Kara Sooda sathu parpam for kalladaippu noi Urolithiasis
dc.title.alternative
dc.creator.researcherSudha Revathy S
dc.subject.keywordKalladaippu Noi
dc.subject.keywordKara Sooda Sathu Parpam (KSSP)
dc.subject.keywordPreclinical evaluation
dc.subject.keywordSafety and Therapeutic Efficacy
dc.subject.keywordSiddha Herbo Mineral Compound
dc.subject.keywordUrolithiasis
dc.description.note
dc.contributor.guideMurugesan M
dc.publisher.placeChennai
dc.publisher.universityThe Tamil Nadu Dr. M.G.R. Medical University
dc.publisher.institutionDepartment of AYUSH
dc.date.registered
dc.date.completed2015
dc.date.awarded
dc.format.dimensions
dc.format.accompanyingmaterialNone
dc.source.universityUniversity
dc.type.degreePh.D.
Appears in Departments:Department of AYUSH

Files in This Item:
File Description SizeFormat 
01_title.pdfAttached File131.68 kBAdobe PDFView/Open
02_certificate.pdf287.4 kBAdobe PDFView/Open
03_preliminary pages.pdf3.35 MBAdobe PDFView/Open
04_chapter 1.pdf27.2 kBAdobe PDFView/Open
05_chapter 2.pdf15.12 kBAdobe PDFView/Open
06_chapter 3.pdf376.66 kBAdobe PDFView/Open
07_chapter 4.pdf14.03 kBAdobe PDFView/Open
08_chapter 5.pdf155.81 kBAdobe PDFView/Open
09_chapter 6.pdf117.61 MBAdobe PDFView/Open
10_chapter 7.pdf124.94 kBAdobe PDFView/Open
11_bibliography.pdf112.41 kBAdobe PDFView/Open
12_appendix.pdf5.88 MBAdobe PDFView/Open
80_recommendation.pdf154.93 kBAdobe PDFView/Open


Items in Shodhganga are licensed under Creative Commons Licence Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0).

Altmetric Badge: